Zvonko Miličević

Research interests

Publications

• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

  Diabetes Care · 2023 · 10.2337/dc22-1710

• Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2301972

• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

  The Lancet · 2023 · 10.1016/s0140-6736(23)01053-x

• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

  The Lancet · 2022 · 10.1016/s0140-6736(22)02033-5

• LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

  Cell Metabolism · 2022 · 10.1016/j.cmet.2022.07.013

• Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

  Diabetes Care · 2021 · 10.2337/dc20-1473

• Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

  Diabetes Obesity and Metabolism · 2020 · 10.1111/dom.13979

• Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

  The Journal of Clinical Endocrinology & Metabolism · 2020 · 10.1210/clinem/dgaa863

• Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)32260-8

• Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

  The Lancet Diabetes & Endocrinology · 2018 · 10.1016/s2213-8587(18)30023-8

• Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes ( AWARD ‐9)

  Diabetes Obesity and Metabolism · 2017 · 10.1111/dom.12937

• Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

  The Lancet · 2015 · 10.1016/s0140-6736(15)60936-9

• Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes ( AWARD ‐5): a randomized, phase III study

  Diabetes Obesity and Metabolism · 2015 · 10.1111/dom.12479

• Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

  Diabetes Care · 2014 · 10.2337/dc13-2761

• Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study

  Diabetic Medicine · 2012 · 10.1111/j.1464-5491.2012.03745.x

• Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia

  Diabetes Care · 2011 · 10.2337/dc10-2375

• Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

  Diabetes Care · 2009 · 10.2337/dc08-1671

• Natural History of Cardiovascular Disease in Patients With Diabetes

  Diabetes Care · 2008 · 10.2337/dc08-s240

• A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan

  Diabetes Research and Clinical Practice · 2003 · 10.1016/s0168-8227(02)00202-4

Current projects

No projects listed.